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Abstract: Carbohydrate kinases activate a wide variety of monosaccharides by adding a phosphate
group, usually from ATP. This modification is fundamental to saccharide utilization, and it is likely a
very ancient reaction. Modern organisms contain carbohydrate kinases from at least five main
protein families. These range from the highly specialized inositol kinases, to the ribokinases
and galactokinases, which belong to families that phosphorylate a wide range of substrates.
The carbohydrate kinases utilize a common strategy to drive the reaction between the sugar hydroxyl
and the donor phosphate. Each sugar is held in position by a network of hydrogen bonds to the
non-reactive hydroxyls (and other functional groups). The reactive hydroxyl is deprotonated, usually
by an aspartic acid side chain acting as a catalytic base. The deprotonated hydroxyl then attacks the
donor phosphate. The resulting pentacoordinate transition state is stabilized by an adjacent divalent
cation, and sometimes by a positively charged protein side chain or the presence of an anion hole.
Many carbohydrate kinases are allosterically regulated using a wide variety of strategies, due to their
roles at critical control points in carbohydrate metabolism. The evolution of a similar mechanism in
several folds highlights the elegance and simplicity of the catalytic scheme.
Keywords: phosphorylation; hexokinases; ROK kinases; GHMP kinases; phosphatidylinositol
phosphate kinases
1. Overview and Importance
Monosaccharides play a critical role in every organism on Earth [1]. They underpin energy
generation and central metabolism, and they act as the building blocks for the biosynthesis of
polysaccharides. The importance of saccharides and glycans for human health is highlighted by the
wide range of glycobiology related genetic disorders [1]; these include over 200 known mutations in
glucose-6-phosphate dehydrogenase [2], the most common genetic defect in human enzymes [3]. Many
of the glycobiology reactions that cells perform utilize sugars that are phosphorylated at either terminal
hydroxyl [1]. Phosphorylation of sugars provides two negative charges that prevent passive diffusion
across the cell membrane, enabling intracellular concentration of intermediates [4]. Phosphorylation
at both terminal hydroxyls permits reactions that split saccharides, such as the aldolase-catalyzed
retro-aldol reactions in glycolysis [5]. Carbohydrate phosphorylation is sufficiently fundamental
to cellular function that it is likely to have been developed early in evolution [6]. The reaction is
performed by enzymes from five evolutionarily distinct classes (Table 1, Figure 1). These carbohydrate
kinases transfer the terminal phosphate from a nucleoside triphosphate (usually ATP) to a free sugar
hydroxyl [5]. Defects in carbohydrate phosphorylation have been associated with several diseases; in
particular, autosomal galactokinase deficiencies lead to juvenile cataracts within weeks of birth [7,8],
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and mutations in glucokinase account for 30–50% of cases of maturity onset diabetes of the young [9];
whilst, galactokinase itself and other carbohydrate kinases are targets for novel therapeutics [10–16].
This review will compare the well-described mechanisms of five classes of sugar kinases
(hexokinases, ROK kinases, ribokinases, GHMP kinases, and phosphatidylinositol kinases). Each class
has strong experimental evidence for enzyme specificity, regulation, and catalytic mechanism. Despite
the structural differences between the enzymes, they show many similarities in how they achieve their
functions. This review shows how evolution has achieved the same outcome effectively in several
different protein folds.
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Table 1. Overview of the carbohydrate kinase families.
Carbohydrate
Kinase Family Common Substrates
Native Phosphate
Donors (Minor
Donors in
Parentheses)
Pfam ID References
Hexokinase Glucose, mannose, fructose ATP (ITP) PF00349, PF03727,PF02685 [20–24]
ROK Kinase
Glucose, allose, fructose,
N-acetylglucosamine,
N-acetylmannosamine
ATP
(polyphosphate) PF00480 [17,25,26]
Ribokinase Ribose, 2-deoxy-D-ribose,adenosine
ATP, ADP (GTP,
ribonucleotide) PF00294 [27–32]
GHMP Kinase Galactose, N-acetylgalactosamine, ATP (GTP, ITP) PF00288 [8,33–37]
Phosphatidylinositol
kinase
Phosphatidylinositol,
phosphatidylinositol phosphates ATP (GTP) PF00454, PF01504 [38]
2. Hexokinases
2.1. Overview of the Family
The hexokinases (HK) are perhaps the most familiar carbohydrate kinases. They typically
phosphorylate sugars at the hydroxyl at the opposite terminus to the anomeric carbon (i.e., the
6’-position in a six carbon sugar). These enzymes phosphorylate a wide range of sugars and they
mostly prefer ATP as the phosphate donor [39]. Hexokinases fall into two main classes, traditionally
labelled hexokinase and glucokinase (GK), following the nomenclature of the human isoforms [40].
Eukaryotes generally have multiple HK paralogues and a single GK: the preferred substrate of all these
enzymes is glucose [20]. By contrast, most prokaryotic hexokinases belong to the GK family and have
a wide range of preferred substrates. These substrates include glucose, ribulose, gluconate, xylulose,
glycerokinase, fructose, rhamnose, and fucose [4,20]. Glucokinase activators have been tested in the
clinic as anti-diabetics [14,41,42]; whilst, hexokinase inhibitors have been proposed as therapeutics
targeting eukaryotic parasites that are reliant on glycolysis [11,15].
2.2. Hexokinase Specificity
Hexokinases generally show a moderate specificity for their target sugars, although some are
more promiscuous [43]. Higher eukaryotes, with several hexokinase paralogues, are generally slightly
less specific, phosphorylating mannose and fructose at the 6′-hydroxyl, in addition to glucose [20].
Lower eukarya and bacteria, in contrast, generally have separate enzymes for each substrate, with
higher specificity [20], although some bispecific enzymes have been characterized [20,44]. This pattern
is reversed when considering the phosphate donor specificity. Most eukaryotic hexokinases show a
strong preference for ATP as the phosphate donor (e.g., rat hexokinase has 24-fold lower KM for ATP
when compared to inosine triphosphate, ITP, the next most preferred) [23]. Bacterial hexokinases are
more competent to substitute ATP for ITP or ADP (adenosine diphosphate) [21,22,24].
2.3. Allosteric Regulation of Hexokinases
Many HKs act at important regulation points for cellular biochemical pathways. Consequently,
many are regulated allosterically by feedback mechanisms to ensure appropriate activity. Eukaryotic
hexokinase isoforms I and III contain a second, vestigial HK domain that acts as a binding site for
allosteric effectors [20]. Binding of the product glucose-6-phosphate (Ki ranging from 0.06–3.4 mM)
to this site causes a conformational change that inhibits enzyme activity [45]. This can be alleviated
by binding of the activators phosphate or citrate to the same site [20]. The hexokinase II isoform
lacks this regulatory domain. Many cancers that overuse glycolysis (the “Warburg effect”) therefore
significantly overexpress HK II to drive glycolysis, highlighting the importance of this regulation [46,47].
Yeast HK uses an alternative allosteric regulation, where ATP binds between two HK protomers to
generate a non-symmetric dimer. This dimer shows half-site reactivity, and so the effective enzyme
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rate is reduced to half [48]. GKs, in contrast, are allosterically regulated via GK regulatory proteins
(GKRP), which bind in the absence of glucose [49,50]. GK inhibition by GKRPs is enhanced by the
binding of fructose-6-phosphate (a downstream product of GK activity), but alleviated by fructose-1-
phosphate [12,51]. The allosteric regulation of these enzymes makes them an attractive target for therapy.
2.4. Structure and Catalytic Mechanism of Hexokinases
A wide range of structures of hexokinases from both eukaryotes and prokaryotes has been
determined using X-ray crystallography (e.g., [22,52,53]). The hexokinase fold consists of a large α/β
domain and a small α/β domain, separated by a deep cleft that contains the active site (Figure 2a).
On binding to the sugar substrate to the bottom of the interdomain cleft, there is a rigid body closure
of the domains [54]. A shear movement of the α3 helix and core β-sheet causes four loops of the large
domain to close over the sugar substrate to complete the active site, with two of these (L1, L4) being
highly conserved [45,54]. The induced fit of the enzyme over the sugar is essential to form the functional
nucleotide binding site [45,54]. This site is a deep cleft that is formed between the two domains after sugar
binding. Despite this, hexokinases are generally agreed to show a random sequential mechanism, where
either substrate may bind first [55]. Five conserved motifs bind to the nucleotide, including residues
from both subunits [54], which also coordinate an Mg2+ ion binding to the nucleotide phosphates.
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Figure 2. Structure and mechanism of hexokinases. (a) Hexokinases show a conformational change
on binding substrate to create the ATP binding site. Structures of an apo enzyme (raspberry/orange;
PDB ID: 2E2N) and ligand bound enzyme (teal; PDB ID: 2E2Q [43]). Ligands xylose (white carbons;
substrate analog) and ADP (carbons pink; product). The protein structures have the large domain (left:
teal/raspberry) superimposed to highlight the movement in the small domain (teal/orange). There is
a substantial rigid body closing of the domains to enclose the substrate. (b) Catalytic mechanism.
The reactive hydroxyl (would be located at the red circle, attached to an additional carbon at the
point indicated by the red arrowhead) is deprotonated by an aspartic acid (catalytic base; black arrow;
D95). This will attack the -phosphate of ATP. The pentacoordinate transition state is stabilized by the
metal ion (green sphere) and a positively charged side chain (black dashed arrow; K15). Additional
side chains hold the sugar in position (yellow arrowheads; D74/H94/D140). (c) Generic reaction
mechanism for carbohydrate kinases (hexokinase shown). The reaction is initiated by a catalytic base
abstracting a proton from the reactive hydroxyl (left). The oxygen atom then attacks the -phosphate
of ATP (second left), forming a pentacoordinate transition state (second right). This is stabilized by a
divalent cation, and by the protein (not shown). This transition state resolves leaving ADP and the
phosphorylated carbohydrate (right). Images generated using PyMOL version 1.8 (a,b) and BIOVIA
Draw (version 2017 R2, 3DS, Paris, France) (c).
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The mechanism of catalysis is predominantly a mixture of base catalysis, metal ion catalysis,
and the formation of a near-attack conformation (Figure 2b,c). The 6′ hydroxyl is deprotonated
by a conserved aspartic acid, turning the 6′ O− into a stronger nucleophile. This then attacks the
γ-phosphate of the nucleotide, which is presented by the enzyme in an ideal location for reaction.
The Mg2+ ion and a conserved positively charged side chain [43] stabilize the negative charge of the
ATP and especially the transition state. In human glucokinase, a lysine side chain also acts as a general
acid to protonate the leaving phosphate [56]. As the β-phosphate interacts only with small domain, it
is expected that, after catalysis, the ADP product will be removed from the active site by an outward
movement of the small domain, releasing the sugar-phosphate product [45,54].
3. ROK Kinases
3.1. Overview of the Family
The ROK (repressor, open reading frame, kinase) kinases are predominantly bacterial enzymes
that are structurally related to the HKs [57–59]. These enzymes are generally used to phosphorylate
monosaccharides that are produced from the catabolism of cellular components or complex
polysaccharides that are used as alternative sources of carbon and energy. Known substrates
include glucose [25], allose, fructose [17], N-acetylglucosamine [26], and N-acetylmannosamine [60].
N-acetylglucosamine is of particular relevance for recycling of the peptidoglycan cell wall [26,57]
and the utilization of chitin. They have a particular importance for free-living bacteria that require
flexibility in their food sources.
3.2. ROK Kinase Specificity and Regulation
Few ROK kinases have been extensively characterized for their substrate specificity. Those that
have been studied are selective for a narrow range of related sugars, with little activity against
other sugars [25,57]. Consistent with this, there is good evidence of sequence motifs for binding
different substrates [61]. Most ROK kinases characteristically strongly prefer ATP as a phosphate
donor, and require a magnesium ion in a similar manner to the HKs [58]. However, some of these
enzymes can additionally utilize polyphosphate as a phosphate donor [25]. ADP, in contrast, acts
as a product inhibitor [62]. Archaeal ROK hexokinases and glucokinases show little evidence of
allosteric effects from glycolytic intermediates at physiological concentrations [62]. In contrast, the
ROK glucokinase from the antibiotic producing bacterium Streptomycetes coelicolor is allosterically
regulated (both activated and inhibited) by a variety of five-carbon sugars [63].
3.3. ROK Kinase Structure and Catalytic Mechanism
The ROK kinases have a related structure to the HKs, with a large α/β domain and a small α/β
domain (Figures 1b and 3a). Unlike the HKs, ROK kinases all form dimers: some members form a
tetramer (dimer of dimers) [25]. Two sequence motifs (“ROK motif” (CXCGXXGC) and ATP binding
motif (DXGXT)) are found in the large domain [58,59]. The ROK motif acts as a zinc finger motif and
all ROK kinases include structural zinc. As with the HKs, the carbohydrate binding site is formed at
the cleft between the two domains, with the carbohydrate held in position by amino acid side chains
from both domains [59,64]. Again, in common with the HKs, the binding of the carbohydrate causes
a re-arrangement of the two domains, and the ATP binding site forms only after the carbohydrate
binds. Kinetic analysis indicates that the enzymes show an ordered Bi–Bi sequential mechanism where
the carbohydrate binds first, followed by ATP [64], unlike the hexokinases. A divalent cation is again
required for catalysis: characterized ROK kinases can utilize magnesium or manganese [62]. Similarly
to HKs, ROK kinases catalyze the phosphorylation of carbohydrates using a conserved aspartic acid
to act as a general base and deprotonate the reactive hydroxyl group [17,64]. The negatively charged
oxygen atom then attacks the ATP γ-phosphate, forming the pentacoordinate transition state. This is
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stabilized by the divalent cation, and possibly by positively charged residues located near to the
γ-phosphate [17].
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4. The Ribokinase Family
4.1. Overview of the Family
The ribokinase (RK) family of carbohydrate kinases includes adenosine kinases (AK; this
non-carbohydrate kinase will not be discussed further), fructokinases and phosphofructokinases,
inosine-guanosine kinase, 2-dehydro-3-deoxygluconokinase, and 6-phosphotagatokinases [29].
Enzymes in this family catalyze the phosphorylation of a variety of carbohydrates, nucleosides and
cofactor precursors. Most of these enzymes have broad importance to cells in anabolic reactions
to synthesize amino acids, nucleotides, and thiamine diphosphate [18,65]. An exception is the
phosphofructokinases (PFKs), which are core enzymes in glycolysis [66]. The PFKs are amongst
the best examples of enzyme allosteric regulation.
4.2. Ribokinase Specificity
Most RKs have high specificity towards their substrates, in comparison to similar naturally
occurring molecules. For example, whilst ribokinases will phosphorylate 2-deoxy-D-ribose with
only moderately raised KM in comparison to D-ribose, very low activity is observed with any of the
other D-pentoses or D-fructose [29]. One family of RKs from the archaeal order Methanococcales
contain an adaptation, allowing them to accept both glucose and fructose-6-phosphate as substrates.
These enzymes perform two steps in the classical Embden–Meyerhof–Parnas glycolytic pathway [44,67].
RKs are also considerably more promiscuous in their substrate specificity for the phosphate donor than
HKs. E. coli RK has activity with GTP as a phosphate donor as well as the preferred substrate ATP [28];
whilst, Salmonella typhimurium RK will accept several ribonucleotides and deoxyribonucleotides [30].
Other members of the family (e.g., Trypanosoma brucei adenylate kinase) also accept alternative
nucleotides with KM in the same order of magnitude as ATP [32]. Some unusual ribokinases use
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alternative phosphate donors. Archaeal RKs have been characterized that prefer donors including ADP
and acetyl-phosphate [31]; whilst, an amoebal PFK uses inorganic pyrophosphate as the donor [68].
It is likely that other enzymes in this class have unusual or multiple donors, but these are yet to be
tested for.
4.3. Allosteric Regulation of Ribokinases
Similarly to the HKs, there is strong evidence that some RKs are allosterically regulated, again
reflecting their critical roles in metabolic pathways. Phosphofructokinases are amongst the best
understood allosterically regulated proteins. Both prokaryotic [66,69] and eukaryotic [70] PFKs show
allosteric regulation to feedback through glycolysis. Indeed, eukaryotic PFKs have over 20 known
effectors and two effector binding sites [70]. The E. coli phosphofructokinase-2 shows elegant allosteric
regulation by Mg-ATP (as ATP is both a substrate and the end product of glycolysis). A second Mg-ATP
molecule binds close to the active site, slowing the reaction without competing with the carbohydrate
substrate [71,72]. RKs are allosterically regulated by a range of phosphorylated products [73–75].
These compete for a binding site, with the degree of charge on the phosphorus atom directing either
activation or inhibition [29]. Several RKs also require a potassium ion in a structural role that is close
to the nucleotide binding pocket [76–79]. These mechanisms are very different from those that the HKs
use for control. This reflects that the RK fold offers different opportunities for regulation compared to
the more dynamic HKs.
4.4. Structure and Catalytic Mechanism of Ribokinases
Similarly to HKs, RKs are two-domain proteins, with a large domain and a small domain [80].
The large domain consists of a large β-sheet flanked on both sides of ten α-helices, and contains the
majority of the substrate (carbohydrate and nucleotide) binding sites. The second domain is smaller
in comparison to the large domain than in the HKs. It consists of a core of four β-strands that act
as a lid over the active site (Figure 4a) [18]. Similarly to the HKs, RKs can be monomeric or dimeric.
Ribokinases are generally dimeric, with the protruding β-sheets of the small domains forming an
extended β-clasp that forms the dimer [18]. In contrast, adenosine kinases are monomeric, with
an insert into the small domain blocking the dimerization site [29]. The carbohydrate binding site
lies between the large and small domains, although mostly this is contained in the large domain.
The nucleotide binding site lies in a groove on the large domain adjacent to the carbohydrate binding
sites [18,80]. Unlike the HKs, the two binding sites are present in the apo-protein. However, there is a
conformational change between the two domains on carbohydrate binding, with the small domain
rotating 15–30◦ relative to the large domain to cover the binding site [29,80]. This is a driven by
a series of hydrophobic interactions between the sugar and the lid. This change is not essential to
form the nucleotide binding site [18], but it does increase the enzyme’s affinity for ATP. In RK, the
γ-phosphate group of ATP is brought close to the O5′ atom of the ribose at the edge of the lid, close
to the optimal distance for reaction [76]. The conformational change also affects the catalytic site of
the enzyme, and so it is again required for catalysis. This suggests that RKs will again use an ordered
sequential Bi Bi mechanism [18,29]. RKs also bind a divalent cation, which is essential for function.
Both eukaryotic and prokaryotic ribokinases show a complete loss of catalytic activity without these
cations. Magnesium is preferred for E. coli ribokinase, but a range of other divalent cations can play the
same role as Mg2+ in the enzymatic reaction [29,76,78], such as Mn2+, Co2+, Ca2+, Ni2+, and Cu2+ [28].
Some RKs also require a monovalent cation (usually potassium, but also cesium) to organize the ATP
loops [76,78]. This shapes the nucleotide binding pocket, enhancing both the substrate binding affinity
and the catalytic activity of ribokinases [78]. Additionally, in crystallographic structures, a second ion
that is bound to the phosphates of the nucleotide has been observed ([81,82]). The catalytic relevance
of this remains unclear.
The ribokinase mechanism follows the patterns that were observed for other carbohydrate kinases.
The ternary complex of enzyme, carbohydrate, and ATP creates the ideal microenvironment for the
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phosphoryl transfer. The most strongly conserved residue is an aspartic acid [29,78] (Asp255 in E.
coli ribokinase) that functions as a catalytic base to abstract a proton from the reactive hydroxyl
group [18], as is seen with other carbohydrate kinases (Figures 2c and 4b). This now negatively
charged group makes a nucleophilic attack on the γ-phosphate group of ATP. Allosteric activators
draw the β-phosphate away from the γ-phosphate, weakening the bonds between them and facilitating
catalysis [29]. The pentacoordinate transition state is stabilized by an anion hole that is formed by the
main chain amides from the N-terminal end of α8 [18], and the sidechain of a conserved lysine residue
(Lys43 in E. coli ribokinase) that is also implicated in sugar binding (Figure 4b) [18,78]. The reaction
mechanism for those RKs with good biochemical data is an ordered sequential Bi–Bi mechanism,
where the sugar substrate binds first, followed by ATP [29]. This is consistent with the structural
observations that carbohydrate binding helps to facilitate ATP binding.
Catalysts 2018, 8, x FOR PEER REVIEW  8 of 19 
 
The ribokinase mechanism follows the patterns that were observed for other carbohydrate 
kinases. The ternary complex of enzyme, carbohydrate, and ATP creates the ideal microenvironment 
for the phosphoryl transfer. The most strongly conserved residue is an aspartic acid [29,78] (Asp255 
in E. coli ribokinase) that functions as a catalytic base to abstract a proton from the reactive hydroxyl 
group [18], as is seen with other carbohydrate kinases (Figure 2c/4b). This now negatively charged 
group makes a nucleophilic attack on the γ-phosphate group of ATP. Allosteric activators draw the 
-phosphate away from the -phosphate, weakening the bonds between them and facilitating 
catalysis [29]. The pentacoordinate transition state is stabilized by an anion hole that is for ed by the 
ain chain a ides fro  the -ter inal end of α8 [18], and the sidechain of a conserved lysine residue 
(Lys43 in E. coli ribokinase) that is also i plicated in sugar binding (Figure 4b) [18,78]. The reaction 
echanis  for those RKs ith good bioche ical data is an ordered sequential Bi–Bi echanis , 
here the sugar substrate binds first, follo ed by ATP [29]. This is consistent ith the structural 
observations that carbohydrate binding helps to facilitate ATP binding. 
 
Figure 4. Structure and mechanism of ribokinases. (a) Dimerization of ribokinases. The small -sheet 
domains of two monomers (raspberry and teal) join to form a -clasp. (b) Proposed mechanism for 
ribokinases. The reactive hydroxyl (red circle) is deprotonated by an aspartic acid (catalytic base; 
black arrow; D255). This will attack the -phosphate of ATP. The pentacoordinate transition state is 
stabilized by a lysine side chain (black dashed arrow; K43) and by an anion hole produced by main 
chain amides (white arrowheads). An additional side chain helps to bind the sugar hydroxyls (yellow 
arrow; D16). A divalent cation was not observed in this crystal structure but is essential for catalysis. 
Colors: ligand bound enzyme (teal; PDB ID: 1RKD [18]). Ligands ribose (white carbons; substrate) 
and ADP (carbons pink; product). Images generated using PyMOL version 1.8. 
5. The GHMP Kinase Family 
5.1. Overview of the Family 
A fourth group of carbohydrate kinases belong to the GHMP kinase family (standing for 
galactokinase, homoserine kinase, mevalonate kinase, and phosphomevalonate kinase) [83]. GHMP 
kinases belong to a wider structural fold that includes diverse proteins. These include several 
carbohydrate kinases: in addition to the galactokinase for which the family is named, these include 
N-acetylgalactosamine (GalNAc) kinase [84], galacturonic acid kinase [85], arabinose kinase [86], and 
one group of heptose-7-phosphate kinases [87]. Human galactokinase is important for galactose 
catabolism (via the Leloir pathway), and it has been suggested as a target for drug interventions to 
suppress galactosemia (caused by an accumulation of the product galactose-1-phosphate when the 
next Leloir pathway enzyme is absent) [10,88–90]; or, for use in enzyme replacement therapy in the 
(rarer) galactosemias that is caused by a defect in galactokinase [91]. 
. i i i . i i i i i s. ll β
j t f β .
. The reactive hydroxyl (red cir le) is deprotonated by an aspartic acid (catalytic base; lack
arrow; D255). This will attack the γ-phosphate of ATP. The pentacoordin te transition state is stabilized
by a ysine side chain (black d shed rrow; K43) and by an anion hole produced by main chain amides
(white arrowheads). An additional side chain helps to bind the ugar hydroxyls (yellow arrow; D16).
A divalent cation was ot observed i this crystal structure but i essential for catalysis. Colors: ligand
bound enzyme (teal; PDB ID: 1RKD [18]). Ligands ribose (white carbons; substrat ) nd ADP (carbons
pink; product). Images generated usin PyMOL v rsion 1.8.
5. The GHMP Kinase Family
5.1. Overview of the Family
A fourth group of carbohydrate kinases belong to the GHMP kinase family (standing for
galactokinase, homoserine kinase, mevalonate kinase, and phosphomevalonate kinase) [83]. GHMP
kinases belong to a wider structural fold that includes diverse proteins. These include several
carbohydrate kinases: in addition to the galactokinase for which the family is named, these include
N-acetylgalactosamine (GalNAc) kinase [84], galacturonic acid kinase [85], arabinose kinase [86], and
one group of heptose-7-phosphate kinases [87]. Human galactokinase is important for galactose
catabolism (via the Leloir pathway), and it has been suggested as a target for drug interventions to
suppress galactosemia (caused by an accumulation of the product galactose-1-phosphate when the
next Leloir pathway enzyme is absent) [10,88–90]; or, for use in enzyme replacement therapy in the
(rarer) galactosemias that is caused by a defect in galactokinase [91].
Catalysts 2019, 9, 29 9 of 19
5.2. GHMP Kinase Specificity
Most characterized GHMP carbohydrate kinases have a reasonably tight specificity, targeting
their preferred substrate and very similar molecules. The best characterized are the galactokinases.
Human galactokinase (GALK1) is highly specific for its sugar substrates phosphorylating only
α-D-galactose and closely related analogues, galactosamine, and 2-deoxy-galactose [8]. In contrast,
human N-acetylgalactosamine kinase (GALK2) has broader specificity, and it will phosphorylate both
N-acetylgalactosamine and other sugars that share the 2′-acetylamine modification [92,93]. Prokaryotic
galactokinases have more relaxed substrate specificity, accepting a variety of galactose analogues
as substrates [33,94–97]. Far fewer data are available on the nucleotide specificity of the GHMP
carbohydrate kinases. The available data suggest that they have a strong preference for ATP. One case
of a kinase that can also use GTP and ITP with lower activity has been reported [33]. As with other
carbohydrate kinases, a magnesium ion is also required for activity [87,98].
5.3. Structure and Catalytic Mechanism of GHMP Carbohydrate Kinases
GHMP carbohydrate kinases share the general structure of their wider fold, with two α/β domains
of approximately equal size (Figure 5a). The two domains are not strictly separated in the protein
sequence, with the very C-terminus of the protein contributing to the domain that is largely made
from the N-terminal parts of the protein [99,100]. Some members of the family are monomeric, whilst
others are obligate dimers [36,87]. The protein active site is formed in a cleft between the two domains.
The carbohydrate substrate is held in a deep pocket that is formed between the two domains, whilst the
nucleotide binds along a shallow groove between the two domains with parts of the ribose ring exposed to
solvent [87]. The nucleotide binding site is present before the carbohydrate binds to the enzyme, similarly
to the RKs. This permits different GHMP kinases to show a variety of kinetic mechanisms. Eukaryotic
galactokinases show an ordered mechanism, where ATP binds the enzyme before galactose [100–102], as
do N-acetylgalactosamine kinases [92]. Plant galactokinases and bacterial heptose-7-phosphate kinases
show the opposite mechanism, an ordered mechanism with the carbohydrate binding first [87,103];
whilst, E. coli galactokinase shows a random sequential mechanism [104].
Two amino acid side chains are strongly conserved throughout the GHMP carbohydrate kinases
(aspartic acid and arginine; Figure 5b) [99,100,105]. The aspartic acid coordinates the carbohydrate
substrate 1′ hydroxyl group. This has been proposed to act as a catalytic base [106], deprotonating
the reacting 1′ hydroxyl group to make it a stronger nucleophile to attack the γ-phosphate group of
ATP [87,107]. The arginine coordinates the sugar and the ATP phosphate groups. It is expected to
assist in increasing the pKa of the conserved aspartic acid to make this a better catalytic base [106,107].
Mutation of the conserved aspartate abolished activity in mammalian galactokinases [16,106–108] and
heptose-7-phosphate kinase [87]. Conservative mutation of the conserved arginine showed a small
reduction in catalytic efficiency [107]. Non-conservative mutations abolish activity [87,107], but they
may also reduce enzyme stability. A conserved sequence of three serine residues helps to coordinate a
divalent cation (usually magnesium) and the ATP phosphates [87]. The pentacoordinate transition in
the kinase reaction (Figure 2c) is stabilized by the cation, the conserved arginine, and an anion hole
formed from backbone amides [87,107]. One quantum mechanics/molecular mechanics (QM/MM)
study supported the catalytic base mechanism [107], with the catalytic aspartate polarizing the O-H
bond in the reactive hydroxyl to facilitate catalysis. Another study instead proposed that the reaction
proceeds by direct attack of the hydroxyl oxygen on ATP, with the intermediate stabilized by a pair of
arginine residues [109]. A similar mechanism was proposed for another GHMP kinase [110]. As the
critical proposed catalytic arginine is not conserved [109], and non-conservative mutations have little
effect on catalytic efficiency [105], it is more probable that the true mechanism is a combination of those
proposed (i.e., a catalytic base mechanism assisted by the stabilization of negative charge on the ATP
phosphates). This remains controversial and would benefit from similar detailed studies on a wider
range of GHMP carbohydrate kinases. The catalytic base mechanism is similar to that observed in the
hexokinases, with the aspartic acid and magnesium playing identical roles; whilst, the anion hole is
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similar to that seen in ribokinases. Here, the conserved arginine provides additional catalytic power,
which may reflect the less reactive nature of the anomeric oxygen in comparison to the 6′ oxygen.
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ID: 1WUU [36]). (b) Proposed mechanism for GHMP kinases. The reactive hydroxyl (red circle) is
deprotonated by an aspartic acid (catalytic base; black arrow; D186). This will attack the γ-phosphate
of ATP. The aspartic acid pKa is increased by an arginine residue (black dashed arrow; R37), which
also coordinates the ATP phosphates. The pentacoordinate transition state is stabilized by this arginine
side chain, a cation (green sphere), and by an anion hole produced by main chain amides (white
arrow eads). Additional side chains help to bind the sugar hydroxyls (yellow arrow; E43/D46), the
cation, and the AT phosphates (yellow arrowheads; S140/S141/S142). Colors: ligand bound e zyme
(teal; PDB ID: 1WUU). Ligands galactose (white carbons; ubstrate) and AMP-PNP (carbons pink;
substrate analog). Images generated using PyMOL version 1.8.
6. Phosphatidylinositol Related Kinases (PI-Ks)
6.1. Overview of the Family and Specificity
Phosphatidylinositol (PtdIns) is a inor phospholipid that is found on the cytosolic leaflet of
eukaryotic cellular and organelle membranes. It can be phosphorylated at multiple free hydroxyl groups,
apart from the 2′ and 6′ positions. Alternatively phosphorylated PtdIns are used by eukaryotic cells as
markers of different organelles and as second messengers [111–114]. Phosphorylation of PtdIns has
many important roles in signalling and physiology, with mutations leading to familial diseases [115,116].
This phosphorylation is performed by a distinct class of enzymes, the PtdIns kinases (PI-Ks). These are
divided into the PtdIns-3-kinases (PI3Ks), PtdIns-4-kin ses (PI4Ks), and phosph tidylinositol phosphate
kinases (PIP5Ks) [111]. The PI3K and PIP5K grou s are further cl ssified into t pes I, II, and III,
according to their structural features and lipid substrate preferences [111,117,118]. Type I and type
II PI5Ks generate phosphatidylinositol 4,5-bisphosphate (also kno n simply as PIP2 or PI(4,5)P2)
from phosphatidylinositol 4-phosphate (PI4P or PIP) and phosphatidylinositol 5-phosphate (PI5P),
respectively, whereas the type III produces phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) from
phosphatidylinositol 3-phosphate (PI3P) [119]. Mutations in PI3Ks that enhance activity have a long
history of association with cancer [120–122]. A single class III PI3K ortholog is conserved from lower
eukaryotes to plants and mammals. This class is mainly responsible for the generation of a large fraction
of the PtdIns-3-phosphate, a central phospholipid for membrane trafficking processes [123]. PtdIns
kinases appear to strongly prefer ATP as the phosphate donor [119].
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6.2. Structure and Catalytic Mechanism of PIPKs
The PtdIns kinases are all large, multidomain proteins with substantial regulatory elements.
The PI3K catalytic subunits have a three-domain core structure consisting of a C2 domain, a helical
domain, and a catalytic domain (Figure 6a) [113]. The 110 kDa class I PI3Ks form heterodimers with a
regulatory subunit in the cell [124]. Some isoforms form obligate heterodimers with a single regulatory
partner, whilst the p110γ isoform can choose between several distinct regulatory partners [117].
In contrast, the ~170 kDa class II PI3Ks are monomeric, with an additional large N-terminal region that
lacks homology to other known proteins [114]. Other PtdIns kinases show similar complexes with
regulatory subunits [119,125,126].
The molecular basis for PtdIns kinase catalysis and signaling specificity remains controversial.
Although structures of ligand-free kinases have been solved, these could not confirm the catalytic
residues [127,128]. A recent study by Muftuoglu et al. has suggested a basis for catalysis and specificity
in some PtdIns kinases [119]. Crystallographic analysis of the zebrafish type I kinase PIP5Kα revealed
that a lysine side chain interacts with the ATP γ-phosphate (Figure 6b). This and an arginine side
chain provide a positive charge to stabilize the pentacoordinate transition state. Modeling PI4P into
the PIP5Kα active site of is consistent with the arginine and lysine, also providing affinity for the
monophosphate on the inositol head group. Manganese ions are coordinated by a network of side
chains and they provide further stabilization to the transition state. These side chains are conserved
throughout PIP5Ks, suggesting that ATP binding is similar throughout this family [129]. In contrast,
the lipid sugar has to be arranged such that the reactive hydroxyl is positioned near to the ATP
γ-phosphate. Different substrates have phosphates that are attached to differing positions in the
inositol ring. This ring consequently has to flip 180◦ to project the phosphate of different substrates into
the common binding pocket [119]. A recent mutational and kinetic study on PI3Kα phosphorylation
of PIP2 provided insights into in the catalytic mechanism of this class [129]. A conserved lysine
residue assists in recognition of both ATP and substrate. The proximity of this to the reactive hydroxyl
helps to lower the pKa for this hydroxyl, facilitating proton abstraction. A histidine side chain is
conserved in PI3Ks, but it is not found in related protein kinases. This is proposed to be the PI3K
catalytic base, which deprotonates the reactive hydroxyl in a similar manner to aspartic acids in other
carbohydrate kinases. The reduction in hydroxyl pKa likely allows the less basic histidine to act in
this case (Figure 6c). A second histidine is located close to the ATP γ-phosphate and it likely assists in
stabilizing the pentacoordinate transition state. Kinetic analysis of PI3Kα indicated that this enzyme
shows an ordered sequential mechanism [129].
Catalysts 2018, 8, x FOR PEER REVIEW  11 of 19 
 
6.2. Structure and Catalytic Mechanism of PIPKs 
The PtdIns kinases are all large, multidomain proteins with substantial regulatory elements. The 
PI3K catalytic subunits have a three-domain core structure consisting of a C2 domain, a helical 
domain, and a catalytic domain (Figure 6a) [113]. The 110 kDa class I PI3Ks form heterodimers with 
a regulatory subunit in the cell [124]. Some isoforms form obligat  heterodimers with a single 
regulatory par ner, whilst the p110γ isoform can choose between several distinct regulatory partners 
[117]. In contrast, the ~170 kDa class II PI3Ks are monomeric, with an additional large N-terminal 
region that lacks homology to other known proteins [114]. Other PtdIns kinases show similar 
complexes with regulatory subunits [119,125,126]. 
The molecular basis for PtdIns kinase catalysis and signaling specificity remains controversial. 
Although structures of ligand-free kinases have been solved, these could not confirm the catalytic 
residues [127,128]. A recent study by Muftuoglu et al. has suggested a basis for catalysis and 
specificity in some PtdIns kinases [119]. Crystallographic analysis of the zebrafish type I kinase 
PIP5 α revealed that a lysine side chain interacts with the ATP γ-phosphate (Figure 6b). This and an 
arginine side chain pr v de a positive charge to stabilize the pentacoordinate transition state. 
Modeling PI4P into the PIP5Kα active site f is consistent with the rginin  and lysine, also p oviding 
affinity for the monophosphate on the inositol head group. Manganese ions are coordinated by a 
network of side chains and they provide further stabilization to the transition state. These side chains 
are conserved throughout PIP5Ks, suggesting that ATP binding is similar throughout this family 
[129]. In contrast, the lipid sugar has to be arranged such that the reactive hydroxyl is positioned near 
to the ATP γ-phosphate. Different substrates have phosphates that are attached to differing positions 
in the inositol ring. This ring consequently has to flip 180° to project the phosphate of different 
substrates into the common binding pocket [119]. A recent mutational and kinetic study on PI3Kα 
phosphorylation of PIP2 provided insights into in the catalytic echanism of this class [129]. A 
conserved lysine residue assists in recognition of both ATP and substrate. The prox mity of this to 
the reactive hydroxyl helps to l wer the pKa for this hydroxyl, facilitating ton abstraction. A 
histidine side chain is conserved in PI3Ks, but it is not found in related protein kinases. This is 
proposed to be the PI3K catalytic base, which deprotonates the reactive hydroxyl in a similar manner 
to aspartic acids in other carbohydrate kinases. The reduction in hydroxyl pKa likely allows the less 
basic histidine to act in this case (Figure 6c). A second histidine is located close to the ATP γ-
phosphate and it likely assists in stabilizing the pentacoordinate transition state. Kinetic analysis of 
PI3Kα indicated that this enzyme shows an ordered sequential mechanism [129]. 
 
Figure 6. Structure and mechanism of PtdIns kinases. (a) Overview of PtdIns-3-kinases (PI3K) 
complex with substrate. PI3K is shown as cartoon, with domains shown in different colors (kinase 
domain: purple; regulatory subunit: red). Substrate PIP2 shown in spheres (white carbons). PDB ID: 
4OVV [130]. (b) Proposed mechanism for PIP5K activity. Protein structure is shown in teal; Ligands 
AMP-PNP (carbons pink; substrate analog), selenate (orange selenium, white arrowhead; analog of 
sugar phosphate group) and manganese (purple spheres). A conserved lysine (black arrow; K238) 
and arginine (black arrowhead; R244) coordinate the substrate phosphate, and are essential for 
Figure 6. Structure and mechanism of PtdIns kinases. (a) Overview of PtdIns-3-kinases (PI3K)
complex with substrate. PI3K is shown as cartoon, with domains shown in different colors (kinase
domain: purple; regulatory subunit: red). Substrate PIP2 shown in spheres (white carbons). PDB ID:
4OVV [130]. (b) Proposed mechanism for PIP5K activity. Protein structure is shown in teal; Ligands
AMP-PNP (carbons pink; substrate analog), selenate (orange selenium, white arrowhead; analog of
sugar phosphate group) and manganese (purple spheres). A conserved lysine (black arrow; K238) and
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arginine (black arrowhead; R244) coordinate the substrate phosphate, and are essential for activity.
The lysine will also stabilize the pentacoordinate transition state with the manganese ions. An invariant
aspartic acid (black dashed arrow; D236) is also required for activity, and it is mutated in human disease:
this may contribute to activating the reactive hydroxyl. The manganese ions coordinate to the ATP
phosphates and protein side chains (yellow arrowheads; D299/D378). PDB ID: 5E3U [119]. (c) Proposed
mechanism of PI3Ks. Protein structure colored as (a); ATP (carbons pink, substrate) location taken
from PDB ID: 1E8X [131]. The reactive hydroxyl (red circle) is proposed to be deprotonated by a
histidine side chain (catalytic base; black dashed arrow; H917). This will attack the γ-phosphate of ATP.
A conserved lysine residue (black arrow; K776) coordinates the PIP2. A further conserved histidine
(white arrowhead; H936) is essential for reaction. Additional side chains help to bind the substrate
phosphates (yellow arrowheads; R461/K941). Images generated using PyMOL version 1.8.
7. Perspective and Conclusions
Carbohydrate kinases are attractive targets for therapeutics, with human glucokinase and
galactokinase-1 being particularly actively pursued. They belong to several different structural families
and catalyze reactions on a wide variety of carbohydrate units. Nevertheless, the different structural
classes have all arrived at a very similar catalytic mechanism. In all five cases, the core catalytic
mechanism is the deprotonation of the reactive hydroxyl by a catalytic base. This is usually a highly
conserved aspartic acid, but, in the case of the PtdIns kinases, a positively charged residue from the
conserved sugar phosphate binding pocket increases the sugar hydroxyl acidity allowing for a histidine
to act as the base. Following this, the deprotonated oxygen performs a nucleophilic attack on the ATP
γ-phosphate. Each enzyme stabilizes the pentacoordinate transition state with positively charged
groups: a divalent cation, and in some cases a conserved positively charged side chain. Despite this
strong similarity in the catalytic method, the enzymes show a range of kinetic mechanisms: all are
Bi–Bi enzymes with two substrates and two intermediates, but the order in which the substrates must
bind differs between enzymes. As many carbohydrate kinases are critical decision points in metabolic
pathways, there are clear examples of allosteric regulation from several families. However, even
structurally similar enzymes use very different mechanisms of regulation, suggesting that allosteric
regulation can evolve independently according to the need of the biological system. Carbohydrate
kinases combine elegant simplicity of reaction mechanism and the broad capability for modulation.
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